Development of next-generation gapmer antisense oligonucleotides targeting periostin for intraocular proliferative disease

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15734
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Ophthalmology
• Research Institution: Kyushu University
• Principal Investigator: Yoshida Shigeo 九州大学, 医学研究院, 准教授 (50363370)
• Co-Investigator(Kenkyū-buntansha): 園田 康平 九州大学, 医学研究院, 教授 (10294943) ; 池田 康博 九州大学, 医学研究院, 准教授 (20380389)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: ペリオスチン / 糖尿病網膜症 / 加齢黄斑変性 / アンチセンス

Outline of Final Research Achievements

Recently, a number of studies have demonstrated the effects of anti-vascular endothelial growth factor (VEGF) treatment on intraocular proliferation in eyes with age-related macular degeneration and diabetic retinopathy. However, despite the frequent intravitreal injection of the anti-VEGF drugs, its effect is often limited. As a disease responsible molecule for intraocular ploriferative diseases, we have successfully identified periostin, a matricellular protein. On the other hand, a next-generation gapmer antisense oligonucleotides that is stable with high safety has been recently developed. In this study, the next generation antisense oligonucleotides targeting periostin was synthesized. Periostin-targeting gapmer antisense oligonucleotides significantly inhibited fibrovascular proliferation both in vitro and in vivo models of intraocular proliferation .

Free Research Field

眼科学